Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

NCT04263870 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT04263870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04263870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2020
Completion date
October 31, 2021
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal junction adenocarcinoma, locally advanced unresectable gastric adenocarcinoma, metastatic gastric cancer, stomach adenocarcinoma